Triazolyl derivatives as Syk inhibitors

US9586931B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Merck Canada Inc. · CA

Inventors

• Michelle R. Machacek · Brookline, US
• Eric T. Romeo · Brookline, US
• Solomon D. Kattar · Arlington, US
• Matthew Christopher · Brookline, US
• Michael D. Altman · Cambridge, US
• Alan B. Northrup · Reading, US
• John Michael Ellis · Needham, US
• Brendan M. O'Boyle · Boston, US
• Anthony Donofrio · Cambridge, US
• Jonathan B. Grimm · Ashburn, US
• Michael H. Reutershan · Watertown, US
• Kaleen Konrad Childers · Medfield, US
• Ryan D. Otte · Natick, US
• Brandon D. Cash · Framingham, US
• Yves Ducharme · Montréal, CA
• Andrew M. Haidle · Cambridge, US
• Kerrie Spencer · Woonsocket, US
• Dilrukshi Vitharana · Somerville, US
• Lingyun WU · Shanghai, CN
• Li Zhang · Redwood City, US
• Peng Zhang · Nanhu, CN
• Christian Beaulieu · Laval, CA
• Daniel Guay · Churchill Falls, CA

Key dates

• Filing date: Sep 24, 2013
• Grant date: Mar 7, 2017
• Expiry date: Sep 24, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.